| Type | Public (BSE: 524715) |
|---|---|
| Industry | Pharmaceutical |
| Genre | Generic Pharma Company |
| Founded | Mumbai, India 1983 |
| Founder(s) | Dilip Shanghvi |
| Headquarters | Mumbai, India, India |
| Products | Pharmaceuticals |
| Revenue | 6,079 crore (US$1.16 billion) [1] |
| Net income | 1,816 crore (US$345.04 million) |
| Employees | 10,000 (2010) |
| Website | www.sunpharma.com |
Sun Pharmaceutical (or Sun Pharmaceutical Industries Limited) (BSE: 524715 and scrip ID SUNPHARMA) is an international pharmaceutical company based in Mumbai, India. It should not be confused with Sun Pharmaceuticals Corp, a manufacturer of sun care products owned by the Playtex branch of Energizer Holdings.
Sun Pharmaceutical, often known just as Sun Pharma, makes many generic and brand name drugs that are distributed in the United States, Europe, Asia and worldwide.[2]
Contents |
A planned acquisition of Israeli Taro Pharmaceuticals initiated in March 2007 completed in Sept 2010.[3][4] Taro has a strong franchise in dermatology and topical products, in addition to product baskets in cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taro US has more than 100 ANDA drug approvals in the U.S. alone. One NDA as well as 26 ANDA are awaiting with the USFDA.[5]
On 25 June 2009, US Marshals seized 33 drugs made by Caraco, the subsidiary of Sun Pharma. The seizure was due to the noncompliance of Caraco with the Current good manufacturing practice (cGMP) requirements of the U.S. Food and Drug Administration (USFDA). The seizure was followed by an 18% drop in price of Sun Pharma.[6]